Exploiting immune system specificity to develop soluble molecules that target HBV infected hepatocytes, by Dr Adam Gehring

In Drug Discovery by valerie limLeave a Comment

Dr. Adam Gehring, Assistant Principle Investigator Singapore Insitute for Clinical Sciences, A*Star, Singapore will be presenting on the above topic at Drug Discovery World Asia 2012, part of a series of conferences at 5th Annual BioPharma Asia Convention 2012.

Dr Adam obtained his Ph.D. in the Department of Pathology at Case Western Reserve University (2004) in Cleveland, Ohio, where he studied strategies employed by Mycobacterium tuberculosis to evade detection of the CD4 T cell response. From there Dr Adam joined the UCL Institute of Hepatology (2004-2006) at University College London as a research fellow and shifted interests to viral immunology, which has been the focus of his research since. Dr Adam moved to Singapore in 2006, joining A*Star as a research fellow, and continued his work on the T cell response to viral infection and how this can be exploited for clinical therapy. He is now assistant principal investigator at the Singapore Institute for Clinical Sciences, continuing his work on immunotherapy in chronic viral infections and virus-related cancer.

Dr Adam will be speaking on the following topics:

Exploiting immune system specificity to develop soluble molecules that target HBV infected hepatocytes
1. Understanding the T cell repertoire in HBV infection to choose the best targets
2. Antibody and T cell receptor development and validation
3. Functionalisation and application of the soluble molecules in model systems for pre-clinical development

If you woud like to know more, join us at BioPharma Asia Convention 2012 to gain valuable insights from more than 200 experts. Contact us now for more details!

Leave a Comment

Current ye@r *